New approach aims to shield cancer patients from deadly infections after transplant
NCT ID NCT04237623
Summary
This study is testing whether a drug called sargramostim can help patients recover their immune systems faster and with fewer infections after a stem cell transplant for blood cancer. The transplant uses cells from a partially matched family donor. Researchers will compare this drug to a standard treatment, focusing on how quickly white blood cells return and whether serious infections are reduced. Patients will be followed for one year to monitor survival, cancer relapse, and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSPLANT-RELATED HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northside Hospital
RECRUITINGAtlanta, Georgia, 30342, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.